Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
Biology of Blood and Marrow Transplantation · 2020-07 · 26 (7) · 1312-1317
DOI: 10.1016/j.bbmt.2020.04.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Blood and Marrow Transplantation, 2020-07. Verfasst von Mehdi Hamadani und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; BMT and C…. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
The COVID-19 pandemic has created significant barriers to timely donor evaluation, cell collection, and graft transport for allogeneic hematopoietic stem cell transplantation (allo-HCT). To ensure availability of donor cells on the scheduled date of infusion, many sites now collect cryopreserved grafts before the start of pretransplantation conditioning. Post-transplantation cyclophosphamide (ptCY) is an increasingly used approach for graft-versus-host disease (GVHD) prophylaxis, but the impact of graft cryopreservation on the outcomes of allo-HCT using ptCY is not known. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared the outcomes of HCT using cryopreserved versus fresh grafts in patients undergoing HCT for hematologic malignancy with ptCY. We analyzed 274 patients with hematologic malignancy undergoing allo-HCT between 2013 and 2018 with cryopreserved grafts and ptCY. Eighteen patients received bone marrow grafts and 256 received peripheral blood stem cell grafts. These patients were matched for age, graft type, disease risk index (DRI), and propensity score with 1080 patients who underwent allo-HCT with fresh grafts. The propensity score, which is an assessment of the likelihood of receiving a fresh graft versus a cryopreserved graft, was calculated using logistic regression to account for the following: disease histology, Karnofsky Performance Score (KPS), HCT Comorbidity Index, conditioning regimen intensity, donor type, and recipient race. The primary endpoint was overall survival (OS). Secondary endpoints included acute and chronic graft-versus-host disease (GVHD), non-relapse mortality (NRM), relapse/progression and disease-free survival (DFS). Because of multiple comparisons, only P values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisc…
- Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of…
- Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
- Blood and Marrow Transplant and Cellular Therapy Program, University of Minnesota, Minneapolis, Minnesota.
- Division of Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
- Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Pediatric Hematology/Oncology/Bone Marrow Transplantation, Medica…
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Hamadani, M., Zhang, M. J., Tang, X. Y., Fei, M., Brunstein, C., Chhabra, S., D'Souza, A., Milano, F., Phelan, R., Saber, W., Shaw, B. E., Weisdorf, D., Devine, S. M., & Horowitz, M. M. (2020). Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 26(7), 1312-1317. https://doi.org/10.1016/j.bbmt.2020.04.001
Vancouver
Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation. 2020;26(7):1312-1317. doi:10.1016/j.bbmt.2020.04.001
BibTeX
@article{Hamadani2020,
author = {Hamadani, Mehdi and Zhang, Mei-Jie and Tang, Xiao-Ying and Fei, Mingwei and Brunstein, Claudio and Chhabra, Saurabh and D'Souza, Anita and Milano, Filippo and Phelan, Rachel and Saber, Wael and Shaw, Bronwen E and Weisdorf, Daniel and Devine, Steven M and Horowitz, Mary M},
title = {Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis},
journal = {Biology of Blood and Marrow Transplantation},
year = {2020},
volume = {26},
number = {7},
pages = {1312--1317},
doi = {10.1016/j.bbmt.2020.04.001}
}
EUVIMED